Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Says product sales in the year ended June 30, more than doubled to £4.6 million from £2.3 million the previous year. Revenue in the year totals £4.7 million including licensing income of £600,000, up from £4.4 million the previous year, including licensing income of £2.1 million.

‘We are pleased to have delivered revenues in line with current expectations, reflecting both continued growth in Alkindi as well as the initial roll out of Efmody, primarily in Germany,’ said Interim Chief Executive Officer, Richard Bungay.

Alkindi sales grew 61% year-on-year to £3.7 million.

The firm will report its results for the 18-month period ending December 31 in the first quarter of 2023. Its interim results for the year ended June 30 will be published in September.

Current stock price: 10.53 pence, up 2.7% in London on Tuesday

12-month change: down 83%

Copyright 2022 Alliance News Limited. All Rights Reserved.